clinical trial · NCT07227402
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
Merck Sharp & Dohme LLC·phase3·recruiting·n = 904
Renal Cell CarcinomaBelzutifanZanzalintinibCabozantinib
brief summary
Researchers are looking for more ways to treat advanced renal cell carcinoma (RCC) that is recurrent. Researchers want to learn if recurrent advanced renal cell carcinoma (RCC) responds (gets smaller or goes away) after treatment with belzutifan (MK-6482) and zanzalintinib compared to cabozantinib. The goal of this study is to learn if: People who take belzutifan and zanzalintinib live longer overall and without the cancer getting worse than people who take cabozantinib.
started
Nov 26, 2025
primary completion
Feb 27, 2032
completion
Feb 27, 2032
last updated
Jun 12, 2026
official title
A Phase 3, Randomized, Open-label Study of Belzutifan + Zanzalintinib Versus Cabozantinib in Participants With Advanced RCC Who Experienced Disease Recurrence During or After Prior Adjuvant Anti-PD-1/L1 Therapy (LITESPARK-033)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol